Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer

Authors: Xuewu Nian, Wei Zhang, Limin Li, Yan Sun, Erlin Sun, Ruifa Han

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Nuclear factor-kappa B (NF-κB), a cell survival signal, is involved in carcinogenesis. Polymorphism of NF-κB1 is associated with cancer by several studies. This study aims to perform a comprehensive meta-analysis of studies and determine the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer. Twenty-five case–control studies (7,281 cases and 10,039 controls) were included. We used odds ratios (ORs) to assess the strength of the association, and 95 % confidence intervals (CIs) to identify precision of the estimate. Overall, NF-κB1-94ins/del ATTG promoter polymorphism was significantly associated with decreased susceptibility to cancer in overall population under homozygote (for DD vs. WW: OR = 0.74, 95 % CI = 0.58–0.96), recessive (for DD vs. WD+WW: OR = 0.82, 95 % CI = 0.69–0.99), dominant (for DD+WD vs. WW: OR = 0.84, 95 % CI = 0.71–1.00), and allele (for D vs. W: OR = 0.88, 95 % CI = 0.78–0.98) model. Subgroup analysis for ethnicity found that NF-κB1-94ins/del ATTG promoter polymorphism was significantly associated with decreased susceptibility to cancer in Asians (for DD vs. WW: OR = 0.54, 95 % CI = 0.40–0.74; for WD vs. WW: OR = 0.75, 95 % CI = 0.69–0.81; for DD vs. WD+WW: OR = 0.70, 95 % CI = 0.55–0.90; for DD+WD vs. WW; OR = 0.66, 95 % CI = 0.56–0.78; for D vs. W: OR = 0.75, 95 % CI = 0.65–0.86), but the association was not found in Caucasians. The findings suggest that NF-κB1-94ins/delATTG promoter polymorphism is significantly associated with decreased susceptibility to cancer in overall and Asian population.
Literature
1.
go back to reference Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer. 2010;10:484.CrossRef Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer. 2010;10:484.CrossRef
2.
go back to reference Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol. 1997;29:867–70.CrossRef Barnes PJ. Nuclear factor-kappa B. Int J Biochem Cell Biol. 1997;29:867–70.CrossRef
3.
go back to reference Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 2004;382:393–409.CrossRef Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J. 2004;382:393–409.CrossRef
4.
go back to reference Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol. 2007;133:859–66.CrossRef Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol. 2007;133:859–66.CrossRef
5.
go back to reference Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy. 2009;55:381–5.CrossRef Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy. 2009;55:381–5.CrossRef
6.
go back to reference Cai H, Sun L, Cui L, Cao Q, Qin C, et al. A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol Int. 2013;91:206–12.CrossRef Cai H, Sun L, Cui L, Cao Q, Qin C, et al. A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma. Urol Int. 2013;91:206–12.CrossRef
7.
go back to reference Cheng CW, Su JL, Lin CW, Su CW, Shih CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS ONE. 2013;8:e56130.CrossRef Cheng CW, Su JL, Lin CW, Su CW, Shih CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS ONE. 2013;8:e56130.CrossRef
8.
go back to reference DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRef
9.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRef
10.
go back to reference Fan Y, Yu W, Ye P, Wang H, Wang Z, et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 2011;30:241–5.CrossRef Fan Y, Yu W, Ye P, Wang H, Wang Z, et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 2011;30:241–5.CrossRef
11.
go back to reference He Y, Zhang H, Yin J, Xie J, Tan X, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916–22.CrossRef He Y, Zhang H, Yin J, Xie J, Tan X, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916–22.CrossRef
12.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRef
13.
go back to reference Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45.CrossRef Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45.CrossRef
14.
go back to reference Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.CrossRef Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.CrossRef
15.
go back to reference Kim U, Gunther CS, Roeder RG. Genetic analyses of NFKB1 and OCA-B function: defects in B cells, serum IgM level, and antibody responses in Nfkb1−/−Oca-b−/− mice. J Immunol. 2000;165:6825–32.CrossRef Kim U, Gunther CS, Roeder RG. Genetic analyses of NFKB1 and OCA-B function: defects in B cells, serum IgM level, and antibody responses in Nfkb1−/−Oca-b−/− mice. J Immunol. 2000;165:6825–32.CrossRef
16.
go back to reference Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, et al. Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013;13:549.CrossRef Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, et al. Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 2013;13:549.CrossRef
17.
go back to reference Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007;42:1332–8.CrossRef Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, et al. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol. 2007;42:1332–8.CrossRef
18.
go back to reference Li P, Gu J, Yang X, Cai H, Tao J, et al. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS ONE. 2013;8:e71604.CrossRef Li P, Gu J, Yang X, Cai H, Tao J, et al. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS ONE. 2013;8:e71604.CrossRef
19.
go back to reference Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS ONE. 2012;7:e35078.CrossRef Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS ONE. 2012;7:e35078.CrossRef
20.
go back to reference Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47–54.CrossRef Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, et al. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243:47–54.CrossRef
21.
go back to reference Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery. 2009;145:280–5.CrossRef Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery. 2009;145:280–5.CrossRef
22.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
23.
go back to reference Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene. 1993;8:191–3.PubMed Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene. 1993;8:191–3.PubMed
24.
go back to reference Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55–62.PubMed Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55–62.PubMed
25.
go back to reference Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, et al. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol. 2013;37:634–8.CrossRef Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, et al. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol. 2013;37:634–8.CrossRef
26.
go back to reference Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381.CrossRef Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381.CrossRef
27.
go back to reference Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–60.CrossRef Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4:850–60.CrossRef
28.
go back to reference Riemann K, Becker L, Struwe H, Nuckel H, Duhrsen U, et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics. 2006;16:783–8.CrossRef Riemann K, Becker L, Struwe H, Nuckel H, Duhrsen U, et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics. 2006;16:783–8.CrossRef
29.
go back to reference Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, et al. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther. 2007;45:423–30.CrossRef Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, et al. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther. 2007;45:423–30.CrossRef
30.
go back to reference Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, et al. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013;77:162–8.CrossRef Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, et al. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013;77:162–8.CrossRef
31.
go back to reference Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705–16.CrossRef Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705–16.CrossRef
32.
go back to reference Song S, Chen D, Lu J, Liao J, Luo Y, et al. NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS ONE. 2011;6:e21726.CrossRef Song S, Chen D, Lu J, Liao J, Luo Y, et al. NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS ONE. 2011;6:e21726.CrossRef
33.
go back to reference Tang T, Cui S, Deng X, Gong Z, Jiang G, et al. Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol. 2010;29:9–12.CrossRef Tang T, Cui S, Deng X, Gong Z, Jiang G, et al. Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol. 2010;29:9–12.CrossRef
34.
go back to reference Ungerback J, Belenki D, Jawad ul-Hassan A, Fredrikson M, Fransen K, et al. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 2012;33:2126–34.CrossRef Ungerback J, Belenki D, Jawad ul-Hassan A, Fredrikson M, Fransen K, et al. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis. 2012;33:2126–34.CrossRef
35.
go back to reference Wang X, Lu P, Xu L, Xu Y, Shi Z, et al. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case–control studies. Asia Pac J Cancer Prev. 2011;12:2479–84. Wang X, Lu P, Xu L, Xu Y, Shi Z, et al. Updated meta-analysis of NFkappaB1 -94ins/Delattg promoter polymorphism and cancer risk based on 19 case–control studies. Asia Pac J Cancer Prev. 2011;12:2479–84.
36.
go back to reference Zhang P, Wei Q, Li X, Wang K, Zeng H, et al. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet. 2009;191:73–7.CrossRef Zhang P, Wei Q, Li X, Wang K, Zeng H, et al. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet. 2009;191:73–7.CrossRef
37.
go back to reference Zhou B, Qie M, Wang Y, Yan L, Zhang Z, et al. Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol. 2010;21:506–11.CrossRef Zhou B, Qie M, Wang Y, Yan L, Zhang Z, et al. Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol. 2010;21:506–11.CrossRef
38.
go back to reference Zhou B, Rao L, Li Y, Gao L, Wang Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett. 2009;275:72–6.CrossRef Zhou B, Rao L, Li Y, Gao L, Wang Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett. 2009;275:72–6.CrossRef
39.
go back to reference Zhou B, Rao L, Peng Y, Wang Y, Li Y, et al. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet. 2009;10:47.CrossRef Zhou B, Rao L, Peng Y, Wang Y, Li Y, et al. Functional polymorphism of the NFKB1 gene promoter is related to the risk of dilated cardiomyopathy. BMC Med Genet. 2009;10:47.CrossRef
40.
go back to reference Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, et al. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens. 2011;77:9–17.CrossRef Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, et al. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens. 2011;77:9–17.CrossRef
Metadata
Title
Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer
Authors
Xuewu Nian
Wei Zhang
Limin Li
Yan Sun
Erlin Sun
Ruifa Han
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2470-3

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine